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Abstract:  Botulinum neurotoxins are highly effective therapeutic products. Their 
therapeutic success results from highly specific and potent inhibition of neurotransmitter 
release with a duration of action measured in months. These same properties, however, 
make the botulinum neurotoxins the most potent acute lethal toxins known. Their toxicity 
and restricted target cell activity severely limits their clinical utility. Understanding the 
structure-function relationship of the neurotoxins has enabled the development of 
recombinant proteins selectively incorporating specific aspects of their pharmacology. The 
resulting proteins are not neurotoxins, but a new class of biopharmaceuticals, Targeted 
Secretion Inhibitors (TSI), suitable for the treatment of a wide range of diseases where 
secretion plays a major role. TSI proteins inhibit secretion for a prolonged period following 
a single application, making them particularly suited to the treatment of chronic diseases. A 
TSI for the treatment of chronic pain is in clinical development. 
Keywords: botulinum neurotoxins; biologics; protein therapeutics; recombinant proteins; 
genetic engineering; SNARE proteins 
 
1. Introduction 
Botulinum neurotoxins (BoNTs) are clinically valuable for treating various neuromuscular and 
autonomic conditions, and, as clinical products, have sales of more than a billion U.S. dollars [1]. 
Neurotoxins are clinically effective because they are potent and selective inhibitors of acetylcholine 
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(ACh) release from peripheral nerves, and have a duration of action following a single administration 
that is often measured in months [2]. The therapeutically useful potency and duration of the 
neurotoxins’ activity limit their application, however, because they are responsible for the inherent 
toxicity of the neurotoxins that restrict their therapeutic window. Furthermore, despite targeting a 
universal mechanism of secretion in eukaryotic cells, the cellular selectivity of the neurotoxins limits 
their use to treating conditions involving cholinergic nerve activity. There exists, therefore, an 
opportunity to engineer novel proteins which retain the desirable pharmacological activities of the 
neurotoxins while reducing their toxicity and broadening their range of therapeutic applications. 
Recent developments in understanding the structure-function relationships of the neurotoxins, 
combined with genetic engineering and molecular biology techniques, have made this opportunity a 
reality. Novel recombinant proteins are now entering the clinic that deliver the benefits of the 
neurotoxin pharmacology to a wider range of clinical applications without the inherent toxicity of the 
native neurotoxins. These developments are opening up a new generation of potent biologics for 
treating chronic diseases. 
2. Natural History of the Neurotoxins 
BoNTs are produced by anaerobic, spore-forming, gram-positive bacteria of the genus Clostridium, 
specifically by several strains of C. botulinum, C. butyricum and C. argentinense. To date, seven 
immunologically-distinct forms of BoNT have been identified based upon serological cross-reactivity: 
serotypes A, B, C1, D, E, F and G. Within the serotypes, multiple sub-serotypes have been defined 
based upon sequence homology [3]. A closely related neurotoxin is tetanus toxin (TeNT) produced by 
Clostridium tetani. All BoNTs and TeNT share similar structures and modes of action and are 
collectively known as clostridial neurotoxins (CNTs) [2]. CNTs are 150 kDa di-chain proteins 
produced as single-chain polypeptides, and subsequently cleaved by either bacterial or host-organism 
proteases to form the active, disulfide linked di-chain form of the toxin.  
BoNTs inhibit ACh release from the pre-synaptic terminals of peripheral cholinergic neurons, 
particularly the motor-end plates of motor neurons. This results in flaccid paralysis. By contrast, TeNT 
inhibits the release of glycine from inhibitory Renshaw cells in the ventral motor horn of the spinal 
cord. This results in a dis-inhibition of motor-neuron activity and the characteristic spastic paralysis of 
tetanus. Despite the contrasting symptoms of botulism and tetanus at the whole animal level, at the cellular 
and molecular level the CNTs have very similar mechanistic and biochemical actions—inhibition of 
neurotransmitter release from their respective target neurons [2]. Notably, CNTs are not cyto-lethal 
toxins. Neither BoNTs nor TeNT kill their target neuron, rather they lead to death of the host via a loss 
of motor function that results from selective inhibition of neurotransmitter release. Another important 
aspect of CNT biology is the prolonged, but finite, period of inhibition of neurotransmitter release 
following intoxication of a neuron. With BoNT, inhibition of ACh release and consequent flaccid 
paralysis can last from a week to several months depending upon the serotype [4,5]. Similarly,   
TeNT-induced muscle spasms can last for three to four weeks and then, once the spasms subside, 
recovery takes several months [6]. With both botulism and tetanus, because of the severity and 
duration of the disease, people must be treated in a hospital and often require intensive care and 
respiratory support for several weeks [7,8].  Toxins 2010, 2                                       
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The lethal dose of BoNT for humans is not known, but
 can be estimated from primate studies. The 
potency varies between serotypes, with BoNT/A being the most potent in humans. By extrapolation, 
the
 lethal amounts of crystalline BoNT/A for a 70 kg human
 would be approximately 0.09–0.15 µg 
intravenously and 70 µg orally. This makes it the most potent acute lethal toxin known. Given its 
extreme potency, and routes of intoxication, BoNT is a potential bio-warfare agent and bioterrorist 
threat agent [7]. 
3. Clinical Use of the Botulinum Neurotoxins 
Despite the inherent toxicity of BoNTs and the severe and often fatal nature of botulism, BoNT has 
become a blockbuster therapeutic and a mainstay for treating many debilitating conditions caused by 
neuronal hyperactivity.  
3.1. History and Background 
Christian Andreas Julius Kerner published the first clinical account of a food-borne botulism 
outbreak in 1817. He extracted the active substance from contaminated food and studied its effects, 
both in animals and on himself, and in 1822 suggested that the physiological effects of BoNT could be 
put to therapeutic use [9]. He predicted the toxins’ clinical utility not only in conditions of muscular 
hypercontraction, but also in autonomic conditions of glandular hyperescretion, such as hyperhidrosis 
and hypersalivation. 
It was more than 150 years, however, before this prophetic proposal was realized. In 1980, Alan 
Scott of the Smith Kettlewell Eye Research Institute, San Francisco, published a report on the local 
injection of BoNT/A into ocular muscles to correct strabismus in patients [10,11]. Following this 
pioneering work, clinicians began to explore how BoNT could be used in the clinical treatment of 
numerous other conditions, not just muscle hyperactivity. These include conditions of smooth muscle 
hypercontraction, such as achalasia, and also hyperhidrosis (excessive sweating) and hypersalivation. 
Thus, since Scott’s original groundbreaking work, the ability of BoNT to paralyze skeletal and 
autonomic function has been used to clinically treat an increasing range of conditions [1,12,13]. The 
neurotoxin has also been used for cosmetic purposes, such as treating facial wrinkles like frown lines 
and brow furrows [14,15]. 
3.2. The Clinical Products 
The U.S. Food and Drug Administration (FDA) first approved BoNT/A in 1989 as an orphan drug 
called “Oculinum”, later marketed by Allergan Inc. as Botox
®. In 1997, Allergan introduced a new 
Botox
® formulation with reduced ancillary proteins and lower immunogenic potential [16]. In the 
United Kingdom, a therapeutic formulation of BoNT/A, now marketed as Dysport
® by Ipsen Ltd., was 
developed [17]. 
Botox
® (onabotulinumtoxinA) and Dysport
® (abobotulinumtoxinA) consist of a purified neurotoxin 
complex, which includes the neurotoxin protein and associated non-toxic proteins. The non-toxic 
proteins are believed to help protect the neurotoxin from the harsh environment of the gut during 
natural intoxication. Xeomin
® (incobotulinumtoxinA) is a recently developed formulation of purified Toxins 2010, 2                                       
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BoNT/A without the non-toxic proteins [18]. A second purified BoNT/A product, PurTox
®, is   
in development. Other BoNT/A products, available in parts of Asia, include CBTX-A and   
Neuronox
® [19]. While the most commonly-employed therapeutic BoNT serotype is type A, there is 
also a BoNT/B product, again a purified complex, marketed as Neurobloc
® in Europe and Myobloc
TM 
in the United States [20]. There are no clinically approved products of the other five serotypes, though 
exploratory pre-clinical studies have investigated some of the characteristics of the protein family, for 
example with respect to duration of action [21–25].  
Although, with the exception of Neurobloc
®/Myobloc
TM, all the commercially-available BoNT 
products are type-A based, they are not directly interchangeable [26–30]. The unit of activity for 
measuring the potency of the different preparations is the mouse LD50 (one unit is the amount of 
intraperitoneally-injected toxin that kills 50% of a group of mice). Due to differences in the method of 
production, formulation and performance of the LD50 assay, the units for a given product are not 
clinically equivalent to those of another product. It is therefore critically important to recognize that 
each product requires different unit doses to achieve an equivalent, safe clinical effect. The   
various BoNT/A products are distinct and unique, and should not be considered as generically   
equivalent products.  
3.3. Neuromuscular Uses 
Treatment of muscle hyperactivity continues to be the main use of BoNT and the basis of its 
regulatory approval. Following Scott’s pioneering studies in strabismus, BoNT/A was shown to relieve 
the muscle spasm involved in various focal dystonias. In 1987, ophthalmologist Jean Carruthers 
initiated the cosmetic use of Botox
® when she observed during treatment of blepharospasm that 
vertical glabellar creases (frown lines) disappeared [31]. In addition to dystonia, BoNT injections can 
treat other movement disorders such as tremors of the hands and head, and also motor dysfunctions 
associated with Tourette syndrome.  
As well as involuntary movement disorders, BoNT has been used to treat muscle tone disorders, 
including spasticity associated with cerebral palsy, stroke, brain trauma and multiple sclerosis [32–34]. 
Treatment of leg spasticity in children with cerebral palsy with BoNT means surgical lengthening of 
the heel cord to improve gait can be avoided [35,36]. Early use of BoNT treatment in these children 
may also prevent musculoskeletal deformities and other orthopedic problems later in life. Several 
studies have shown BoNT can improve functionality in spasticity, particularly of the upper limbs, 
following stroke [32]. When used early, BoNT may prevent development of complications of 
spasticity such as contractures. Following BoNT therapy, relief of the rigidity associated with various 
parkinsonian disorders and stiff person syndrome has also been reported [32].  
3.4. Autonomic and other Non-Neuromuscular Uses  
Several studies have reported that following BoNT application to treat muscle spasm, associated 
pain is relieved [27,37]. Among the musculoskeletal and muscle spasm associated pain disorders 
reported to benefit from BoNT injection are low back pain, fibromyalgia-myofascial pain, 
temporomandibular joint and orofacial pain [27]. There have also been several studies reporting BoNT 
can treat muscle contraction headaches (chronic daily, tension or cervicogenic headaches) and Toxins 2010, 2                                       
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migraines [27]. Allergan Inc. have progressed Phase III studies and have received approval from the 
U.K. Medicines and Healthcare products Regulatory Agency (MHRA) of Botox
® as a preventive 
treatment for chronic migraine headaches. Data supporting the clinical studies have been reported [38]. 
The FDA is soon to announce whether the product is approved for use in the United States. 
Interestingly, the pain relief following BoNT administration tends to start earlier and end later than the 
muscle relaxation. This has led to the conclusion that the pain-relieving activity of BoNT is a result of 
mechanisms other than direct muscle relaxation, and several mechanisms have been proposed. These 
include a direct effect on the release of nociceptive neurotransmitters from the peripheral terminals of 
sensory nerves [39,40], thereby reducing local neurogenic inflammation and pain [41]. Alterations in 
the firing activity of supra-spinal afferent projections from muscle spindle fibres could also affect 
central sensory processing [42]. Whatever the explanation, the potential for BoNT to relieve certain 
pain conditions associated with muscle spasm continues to be actively investigated [27,43].  
Given that BoNT inhibits ACh release at cholinergic parasympathetic and post-ganglionic 
sympathetic nerves, it is an effective treatment for several disorders of the autonomic nervous   
system [29,43,44]. Intradermal injection of BoNT is a highly effective treatment for focal 
hyperhidrosis. Whilst for the majority of applications the clinical benefit of BoNT/A is of the order of 
three months, in hyperhidrosis the benefit has been reported to last up to three years [44]. Other 
autonomic applications of BoNT include treating hypersalivation associated with Parkinson’s disease, 
hyperlacrimation and Frey’s syndrome. 
The ability of BoNT injections to relax or inhibit smooth muscle contractility and treat several 
gastrointestinal disorders has also been investigated [45]. Dysphagia, achalasia and other esophageal 
spasms have all been successfully treated with local BoNT injections, as has spasm of the sphincter of 
Oddi, spasm of the rectal sphincter and chronic anal fissure. There have also been several interesting, 
recent reports that injecting BoNT/A into the gastric antrum using endoscopy can treat obesity [46]. In 
laparatomized rats, gastric injection of BoNT/A was reported to significantly reduce their food intake. 
The human clinical studies reported to date, however, have yielded conflicting results. This, therefore, 
remains an interesting potential area for therapeutic use of BoNT. 
Currently, one of the most active and exciting areas of development for the clinical utility of BoNT 
outside of musculoskeletal applications is in urology [47]. Patients with neurogenic bladder suffer 
from detrusor overactivity, which may be combined with detrusor sphincter dyssynergia. Both 
conditions lead to high intravesical pressure and incontinence. In patients with detrusor overactivity, 
BoNT injection at perhaps 20 to 30 sites in the detrusor muscle under cystoscopic guidance has been 
shown in several studies to improve continence, void volume, urinary frequency and bladder capacity. 
BoNT has also been reported to have led to benefit in patients suffering from detrusor sphincter 
dyssynergia following spinal cord injury. In its recent assessment of BoNT in the treatment of 
autonomic disorders, the American Academy of Neurology concluded that: “BoNT should be offered 
as a treatment option for the treatment of … detrusor overactivity … [and] … detrusor sphincter 
dyssynergia after spinal cord injury” [43]. 
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4. Newer Applications and Future Developments 
There has been a huge increase in the range of medical disorders for which therapeutic use of BoNT 
has been explored and demonstrated since 1980, and there continue to be reports of new applications 
[1,29,48]. The clinical utility of this remarkable agent is expected to continue to expand for the 
foreseeable future. One area that will be important in the future will be to properly assess the 
comparative clinical effectiveness of the various BoNT products available and to assess the effect and 
role of the ancillary proteins on the clinical properties of the products [19,29]. In recent years, it has 
become apparent that, within serotypes, there are multiple sub-serotypes that differ in biochemical 
properties [3,49,50]. These sub-serotypes may provide different therapeutic opportunities from current 
products. All of the commercially available BoNT/A products are based upon sub-type A1. Recent 
preliminary clinical studies with a type A2 neurotoxin may indicate clinically meaningful differences 
from the A1 products [51].  
Improvements in the understanding of the toxin serotypes and subtypes promise to further expand 
the clinical value of BoNT as a therapeutic agent. They will not, however, address fundamental 
limitations inherent in the neurotoxin. These limitations derive from the properties that make BoNT 
such a successful product, namely its potent and prolonged inhibition of peripheral cholinergic 
neurotransmission [2]. The potency of neurotoxins results from their high affinity selective binding to 
specific receptors on their target neurons. As a result of this selectivity, the unique ability of CNT, 
including BoNTs, to inhibit secretion cannot be applied to non-neuronal targets [2]. The potency and 
duration of effect of the neurotoxins also means that they have a very narrow therapeutic window and 
can be severely toxic if incorrectly used [52]. There have been reports of severe and even fatal 
outcomes of incorrect administration of BoNT products, and the FDA has recently required a black 
box warning to be included in licensed BoNT products [53]. There is, therefore, a tremendous 
opportunity to develop novel biologics that retain the therapeutically successful pharmacological 
properties of the BoNT products, but which have improved profiles in regard to both therapeutic 
window and breadth of therapeutic opportunity. Recent developments in the understanding of the 
detailed mechanism of neurotoxin function coupled to an understanding of the structural basis of that 
activity have made that opportunity a reality.  
5. Molecular Basis of Neurotoxin Action 
5.1. SNARE Cleavage and Role of SNARE Proteins 
Inhibition of neurotransmitter release by the CNTs is driven by the proteolytic cleavage of SNARE 
(soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins [2]. The SNARE 
proteins are a large superfamily of proteins that are key to membrane fusion in eukaryotes [54–56]. 
Specific SNARE proteins present on two opposing membranes interact to form a stable SNARE 
complex that leads to membrane fusion. Formation of a SNARE complex is sufficient to drive 
membrane fusion [57–59]. The CNTs are Zn
2+-dependent metallo-proteases that have evolved to 
selectively cleave SNARE proteins involved in the docking and fusion of synaptic vesicles with the 
pre-synaptic membrane in their target neurons. Each CNT cleaves one or other of the SNARE proteins 
at a single peptide bond [2]. The exact identity of the SNARE protein and the peptide bond that is Toxins 2010, 2                                       
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cleaved varies between CNTs, but in each case cleavage prevents formation of a productive SNARE 
complex and vesicle fusion, and thereby inhibits neurotransmitter release. 
Although the SNARE proteins and their role in secretion were first identified in neuronal cells, the 
SNARE complex is not restricted to nerve cells [60]. It is a universal mechanism underpinning 
secretion from all cell types. In fact, secretion is not the only SNARE protein-dependent vesicle fusion 
event at the cell membrane. The transport of a wide number of integral membrane proteins to the cell 
surface is mediated via SNARE protein-dependent vesicle fusion. In particular, the regulated 
expression of many receptors, ion channels and transport proteins involves SNARE-dependent fusion 
of intracellular vesicles [55]. Examples include the insulin-regulated expression of the glucose 
transporter Glut4 in adipocytes [61] and the up-regulation of the ion channel TRPV1 in sensory 
neurons [62,63], both of which have been shown to be sensitive to SNARE protein cleavage by 
endopeptidases from CNTs. CNT endopeptidases therefore can affect many vesicular transport 
activities within different cells. The reason that CNTs do not affect these events in non-nerve cell types 
is because they have evolved to specifically bind to nerve cells.  
5.2. Molecular Basis of Neurotoxin Action  
The di-chain CNT protein consists of a light chain (LC) of approximately 50 kDa and a heavy chain 
(HC) of approximately 100 kDa [64]. The LC is a Zn
2+-dependent metallo-protease responsible for the 
SNARE cleavage by the neurotoxin. In order to access its substrate protein and cleave the SNARE 
protein, the LC has to gain entry into the cytosolic compartment of the pre-synaptic nerve terminal. 
The HC is effectively a delivery vector that binds with high affinity to receptors on the pre-synaptic 
membrane and subsequently enables delivery of the LC into the neuronal cytosol.  
The binding event underpins both the highly selective neuronal targeting and the potency of the 
neurotoxins. A dual receptor model of interaction has been proposed, in which the neurotoxins initially 
interact with polysialogangliosides, particularly GD1b and GT1b, at the pre-synaptic terminal [65]. 
The neurotoxin then binds with high affinity to a protein receptor that leads to internalization into an 
intra-cellular vesicular compartment. For BoNT/A, the protein receptor has been identified as an intra-
lumenal domain of the synaptic vesicle protein SV2 [66]. Glycosylated forms of SV2A and SV2B 
have been identified as the protein receptors for BoNT/E [67] and recently glycosylated SV2 has  
also been reported to be the receptor for BoNT/F [68]. A lumenal domain of the synaptic vesicle 
protein synaptotagmin I or II has been identified as the protein receptor for both BoNT/B [69,70]  
and /G [71–73]. The identity of the protein receptor has not yet been determined for the other CNTs. 
The fact that the receptors identified to date are lumenal domains of synaptic proteins is consistent 
with the property of neurotoxins that they are more effective at inhibiting active neurons [74–78].  
Following acidification, the HN domain of HC forms a pore in the vesicle membrane, allowing entry 
of the LC into the cytosol [79]. A key feature of both botulism and clinical neurotoxin therapy is a long 
duration of inhibition of neurotransmitter release [22]. Although the different serotypes vary 
considerably in the duration of this effect, all inhibit neurotransmitter release from several days to 
weeks following a single administration. Whilst the exact molecular basis of this prolonged duration 
and the explanation for the differences observed between serotypes is still an area of active Toxins 2010, 2                                       
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investigation [64], survival of the LC [5,80] and its SNARE protein cleavage products [81,82] within 
the nerve terminal are key factors. 
The first reported crystal structure for a CNT was for BoNT/A [83]. Subsequently, the structures of 
a number of other CNTs, or fragments thereof, have been reported (Table 1). These structures show 
that, despite considerable heterogeneity at the primary sequence level, the different serotypes display a 
highly-conserved multi-domain tertiary structure [64]. To date, the most dissimilar structure reported is 
that for BoNT/E, which, while displaying the same domains as identified in the other CNT structures, 
has a distinct spatial arrangement of the domains within the overall global fold of the protein [84,85]. 
The solution of the tertiary structure of neurotoxin protein has enabled a very close correlation of 
structure to function for the various domains.  
Table 1. CNT structures in the Research Collaboratory for Structural Bioinformatics protein databank. 
Domain/Fragment  Serotypes studied 
BoNT  A, B, E 
LC  A, B, C, D, E, F, G, TeNT 
HC or HC  A, B, C1, D, F, G, TeNT 
LHN  A, B 
The HC consists of two distinct domains: the carboxy terminal half, HC, and the amino-terminal 
half, HN. HC further comprises two sub-domains, each of approximately 25 kDa: the extreme   
carboxy-sub-domain, HCC, and the HCN sub-domain. The HCC sub-domain is where the ganglioside and 
protein binding sites are located [64]. The precise function of the HCN sub-domain is currently 
unknown, although it may help orientate the binding domain relative to the translocation domain and 
enable efficient insertion of the translocation domain [84]. In BoNT/A and /B, the binding and 
catalytic domains flank the translocation domain and there is no interaction between them. In BoNT/E, 
by contrast, the binding and catalytic domains are on the same side of the translocation domain and all 
of the domains interact, resulting in a tight globular structure [84]. The arrangement of the domains in 
the BoNT/E structure may represent a translocation competent conformation enabling more rapid entry 
of BoNT/E LC, explaining the faster toxic rate of BoNT/E relative to other serotypes [84]. 
The HN domain is the translocation domain and consists of two long α-helical regions. Acidification 
of the endosomal compartment following internalization of the bound toxin triggers the HN domain to 
undergo a conformational change enabling insertion into the vesicle membrane [86]. An unusual 
feature of the HN domain is a long loop, aptly referred to as the belt, which wraps around the LC 
domain. It has been proposed that this belt region acts as a surrogate pseudosubstrate LC inhibitor, 
protecting the active site and acting as a chaperone during the translocation process [79,87]. The HN 
channel of BoNT/A has an estimated diameter of 15 Å, which is too small for the LC to pass through 
without unfolding, and there is evidence that under the low pH conditions prevailing in the endosome, 
the LC adopts a molten globule-like structure [88] and translocation occurs via a partially-unfolded LC 
conformation [79]. Translocation of the LC into the cytosol via the HN channel enables the protease to 
access its substrate SNARE protein. 
The LC itself comprises a mixture of α-helices,  β-sheets and strands that form a compact   
globular-like protein structure. There is a large, open cavity, which contains the zinc atom, coordinated Toxins 2010, 2                                       
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by two histidine residues (229 and 233), a glutamate residue (267), and a water-mediated coordination 
through an additional glutamic acid. This region shares structural similarity to the active site of   
Zn
2+-metallo-proteases, such as thermolysin, and contains the characteristic HExxH zinc protease 
consensus motif [2]. Unlike other zinc-dependent proteases, CNT LCs need an extended substrate 
sequence for optimal catalytic activity [89,90]. These include substrate-binding sites remote from the 
scissile bond, and these exosites presumably align the substrate at the catalytic site and are responsible 
for the exquisite substrate selectivity of the proteases [91–93]. 
6. Recombinant Engineering and Application of Neurotoxin Pharmacology 
Understanding CNT structure and its relation to function has opened up the possibility of 
developing recombinant proteins based on the specific pharmacology of the different domains [94]. 
The investment in the basic science of CNT biology over many years provides the potential for the 
design and creation of therapeutic proteins that deliver selected aspects of the neurotoxins’ unique 
pharmacology without the toxicity. The ability to engineer recombinant proteins incorporating specific 
components of the neurotoxins is further aided by the linear organization of the discrete functional 
domains within the neurotoxin gene which enables independent manipulation [95]. Harnessing the 
inherent functional domains of the CNTs both overcomes the limitations of the current neurotoxin 
products and opens up new clinical opportunities.  
6.1. Re-Targeting of Neurotoxin Protease: The Rationale Behind TSIs 
The neurotoxin LC is a highly specific endopeptidase that has evolved to selectively cleave the 
SNARE proteins involved in synaptic vesicle docking and fusion with the pre-synaptic membrane. 
Given, however, that SNARE proteins represent a universal mechanism of vesicle fusion in eukaryotic 
cells [60], underpinning both secretion and the transport of integral membrane proteins to the cell 
surface, the potential exists that neurotoxin LC could cleave SNARE proteins and block vesicle fusion 
events in a variety of cells. Indeed it has been known for many years that, whilst neurotoxins naturally 
only enter neurons to cleave SNARE proteins and block secretion, artificial introduction of the 
neurotoxin, or LC, by microinjection, permeabilization or transfection can affect vesicular trafficking 
in a wide variety of cell types [2]. Delivering the endopeptidase domain to cells not targeted naturally 
by CNTs, for example, non-neuronal cells, is therefore a very exciting way of generating more widely 
applicable therapeutics employing the unique pharmacology of the neurotoxin. Targeted Secretion 
Inhibitors (TSIs) are novel engineered proteins that extend the utility of the CNT LC into a wide 
spectrum of cell types. These proteins incorporate the LC endopeptidase domain and HN translocation 
domain to enable cytosolic delivery, the LHN fragment, together with a binding domain that binds to a 
cell surface receptor on the proposed target cell (Figure 1). By targeting membrane receptors or cell 
surface proteins that internalize into the cell, the HN domain is able to enter a suitable endosomal 
compartment and form a translocation pore thereby enabling entry of the LC into the cytosol. In 
addition to allowing the potent pharmacology of SNARE protein cleavage to be applied to non-
neuronal cells, altering the binding domain also enables creation of neuronally targeted therapeutics 
with improved neuronal selectivity and an enhanced therapeutic window relative to native BoNTs. Toxins 2010, 2                                       
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Figure 1. Schematic representation of Botulinum neurotoxin structure in relation to 
engineered Targeted Secretion Inhibitor (TSI) proteins. (A) Botulinum neurotoxin domain 
structure; (B) TSI engineering. 
 
(A) 
 
(B) 
Botulinum neurotoxins have a very clear structure-function relationship as indicated 
diagrammatically in Figure 1A, where the three discrete domains identified within the crystal structure 
are represented in different colors and their respective functions provided. In TSI proteins, the receptor 
binding domain of the neurotoxin is replaced by a novel protein or peptide binding domain that defines 
new target cell specificity; this is represented diagrammatically in Figure 1B. The engineered TSI 
proteins are created by designing and synthesizing a recombinant gene encoding the desired protein 
and then expressing the gene in a suitable expression host, typically E. coli. 
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6.2. Re-Targeting of Neurotoxin Protease: Development of Recombinant Platform 
Recombinant expression of a catalytically-active, stable LHN fragment of BoNT/A was first 
reported in 2002 [96]. Subsequently, the expression and purification of catalytically active LHN/B and 
LHN/C from E. coli was also reported [97]. The recombinantly expressed LHN proteins were fully 
functional following proteolytic activation to generate the di-chain protein. In all cases, the 
recombinant LHN fragments had very low toxicity, and in the case of recombinant LHN/A, they were 
less toxic than a highly-purified LHN/A prepared by proteolytic treatment of BoNT/A. The LHN 
fragment is effectively non-toxic because it lacks the necessary HC domain with which to bind to 
acceptors on the neuronal surface. The crystal structure for recombinant LHN/A has recently been 
reported [98] and compared to that for BoNT/A. The recombinantly expressed fragment was 
structurally equivalent to the relevant domains within the intact native BoNT. Recombinant LHN/B 
also retains the crystal structure of the equivalent domains in the intact BoNT/B protein [99]. Thus, 
recombinantly expressed LHN proteins retain both the functionality and structure of the relevant 
domains from the parent neurotoxin. 
A fully recombinant fusion protein consisting of the LHN-fragment of BoNT/C1 and epidermal 
growth factor (EGF) has been reported [100]. The protein was expressed as single chain polypeptide 
with a specified enzyme cleavage site between the endopeptidase and the remainder of the polypeptide. 
This enabled selective activation of the expressed protein using a defined exogenous protease to 
produce the active di-chain protein. The potential exists for the linker region containing this activation 
site to be varied to optimize activation of the particular protein and spacer regions can be incorporated 
to optimize the spacing of the various components within the engineered protein. This protein 
represents a prototype example of a TSI protein incorporating relevant components of a clostridial 
neurotoxin, but with modified cell targeting properties allowing targeted delivery of the LC into a 
novel, specified target cell determined by the engineered binding domain.  
6.3. Re-Targeting of Neurotoxin Protease: Proof-of-Concept 
The first description of modifying a CNT’s cell-binding domain was by Bizzini, who, as part of a 
study into the mechanism of tetanus toxicity, designed conjugates coupling either ricin toxin B-chain 
or wheat germ agglutinin to a proteolytically generated fragment of TeNT that retained functional LC 
and HN domains of the neurotoxin [101]. The first retargeted BoNT reported was a conjugate of nerve 
growth factor and LHN/A that was able to deliver the type A endopeptidase into PC12 cells resulting in 
cleavage of SNAP-25 and inhibition of noradrenaline release [102]. Following this, a conjugate of 
wheat germ agglutinin and the LHN/A fragment was reported to deliver the endopeptidase into both 
neuronal and non-neuronal cell types with a consequent cleavage of SNAP-25 and inhibition of 
secretion [103]. One of the cell lines studied was the hamster pancreatic β cell, HIT-T15, where a 
significant concentration-dependent inhibition of stimulated insulin release was found to correlate with 
cleavage of SNAP-25. HIT-T15 cells are resistant to the effects of BoNT/A, so this result 
demonstrated that it is possible to internalize the endopeptidase into the cytosol of a cell normally 
resistant to the effect of BoNT, thus confirming the ability of the HN domain to function in the new 
target cell following binding and endocytosis via the new binding domain. Toxins 2010, 2                                       
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An exciting development of this approach was targeting a conjugate of Erythrina cristagalli lectin 
and LHN/A (ECL-LHN/A) to nociceptive afferents, a therapeutically-relevant target cell, via   
galactose-containing carbohydrates specific to those particular neurons [104]. ECL-LHN/A inhibited 
release of both substance P and glutamate from embryonic dorsal root ganglion neurons in culture. 
Importantly, no effect was seen at equivalent concentrations on cultures of embryonic spinal cord 
neurons from an anatomically adjacent region, thereby demonstrating selectivity of action between 
neuronal populations [104]. The effect in embryonic dorsal root ganglion neurons was maintained for 
at least 25 days following a single treatment, demonstrating that the conjugate had retained the 
duration of effect of the native BoNT. Intrathecally-administered ECL-LHN/A significantly reduced 
the nociceptive inputs to convergent dorsal horn neurons by primary sensory afferents of the C-fiber 
and Aδ types, whereas there was little or no effect on sensory inputs from Aβ-fibers [104]. Intrathecal 
ECL-LHN/A also resulted in prolonged withdrawal latency in a ‘hotplate’ model of acute thermal pain. 
This effect was sustained for more than 30 days post-administration of the conjugate, confirming the 
in vitro finding that the conjugate retained the duration of effect properties associated with the native 
neurotoxin [105]. 
Another approach to generating TSI in which the targeting properties of CNT are modified in order 
to create proteins with differentiated properties and therapeutic potential from native neurotoxins is the 
creation of hybrids between CNTs that combine the properties of the component domains. Delivery of 
TeNT LC to peripheral motor-neurones using BoNT HC has been reported, resulting in a spastic 
paralysis reminiscent of botulism [106]. The creation of chimeras of BoNT/A and /E in which the HC 
domain of one serotype was expressed recombinantly fused to the LHN of the other serotype have also 
been reported [107]. The translocation properties of the hybrid were clearly differentiated, and 
reflected those of the parent LHN domains, whilst the neuronal specificity was influenced by the 
identity of the HC. The therapeutic potential of creating a hybrid neurotoxin TSI in this manner was 
demonstrated by showing that the LHN/E-HC/A hybrid protein was effective at blocking the 
responsiveness of nociceptive neurons to inflammatory or pain stimuli, whereas BoNT/A was 
ineffective [108]. 
With the structural definition of the binding loops within the CNT HC domain and the availability of 
co-crystal structures for many of the interactions with both ganglioside and protein receptors, it has 
been possible to begin to define key residues involved in those interactions [64]. For example, a 
ganglioside binding cavity within the HCC domain of BoNT/A and /B defined by the conserved motif 
H…SXWY…G has been identified [109]. Site directed mutations within this site modified both the 
ganglioside binding affinity and the toxicity of the neurotoxin. Whilst many of the mutants displayed 
reduced binding and toxicity, some displayed an enhanced activity, with the most potent displaying a 
three-fold increased toxicity relative to wild type toxin [110]. This begins to provide a rational basis 
for engineering mutated CNT with modified, particularly enhanced, potency as improved clinical 
products. This would enable reduced dosing and thereby potentially reduce the risk of patients 
developing neutralizing antibodies. Understanding the nature of the binding interactions and 
identification of the binding motifs and key residues also potentially allows the specificity of the 
binding interaction to be modified, although changing the selectivity of the binding event by modifying 
the binding sites has yet to be demonstrated. Toxins 2010, 2                                       
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In addition to engineering the binding domains of CNT to modify functionality and enable creation 
of designed TSI proteins, attention has also been given to the endopeptidase domain and its substrate 
specificity. A major limitation to using clostridial endopeptidases to cleave SNARE proteins and 
thereby inhibit vesicle trafficking in non-neuronal cells is in relation to the SNAP-25 cleaving 
serotypes, BoNT/A, /C and /E. SNAP-25 is restricted in its expression to neurons and the ubiquitously 
expressed homologue, SNAP-23 [111], is not, in man, a substrate for any of the relevant serotypes 
[112]. This means that retargeting the LC from serotypes /A, /C or /E, will not impact vesicular 
trafficking in non-neuronal cells. This limitation to the applicability of clostridial endopeptidase has 
recently been challenged by the reported engineering of a mutated BoNT/E LC that can cleave human 
SNAP-23 [113]. The potential to deliver a mutated LC of serotype E and impact SNAP-23 mediated 
vesicle trafficking is therefore a real possibility, further expanding the opportunity represented by TSI 
to provide novel therapeutic proteins for treatment of chronic diseases not amenable to treatment with 
natural CNT. 
The potential to create novel proteins that enable delivery of the endopeptidase component of a 
CNT to a diverse range of cell types is now well established. The ability of such proteins to produce 
pharmacological effects in disease-relevant animal models, has also established the therapeutic 
potential of this approach. The various studies have demonstrated that the retargeted endopeptidase 
proteins retain the prolonged duration of action that is the hallmark of CNTs. This means that 
recombinant proteins based upon this approach are particularly suitable for treating chronic diseases. 
6.4. Clinical Opportunities for TSIs 
In terms of pre-clinical and clinical exemplification of the TSI platform, a novel targeted BOTOX 
has recently been reported to have completed Phase I studies and to have entered Phase II studies in 
Post-herpetic neuralgia (PHN) [114]. By targeting C fibers and inhibiting release of nociceptive 
neurotransmitter through cleavage of SNARE proteins, it is anticipated that new treatments for chronic 
pain will be developed that harness the extended duration of action of both native neurotoxin and 
future targeted toxin products. It is also reported that a trial of the same targeted BOTOX that is being 
assessed in PHN has also commenced in idiopathic overactive bladder [115]. It is therefore to be 
anticipated that in the foreseeable future, data will begin to emerge that will demonstrate the reality of 
the clinical promise offered by TSI proteins based upon the endopeptidase activity of CNT. A list of 
just some of the potential applications of TSI proteins is illustrated in Table 2.  
Table 2. A selection of potential applications of TSIs. 
Neuronal targeting  Non-neuronal targeting 
Pain Endocrine  diseases 
Idiopathic Overactive Bladder  Inflammation 
Neuropathic Overactive Bladder Mucus  hypersecretion 
 Cancer 
With such broad clinical potential, TSIs are an exciting application of innovative science. As an 
innovative platform, however, it is inevitable that not all of the answers to classic drug development 
questions are yet established in the literature. For example, what is the bioavailability, how stable are Toxins 2010, 2                                       
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the fusion proteins, how well do they reach their specific target in vivo? Pre-clinical observations 
indicate that the receptor binding domain engineered into TSIs is capable of directing the novel protein 
to the target cell of choice and effecting inhibition of secretory processes. As TSI proteins enter 
clinical trials in man data will begin to become available that will address tolerability and safety while 
defining the dose interval and minimal effective clinical dose for clinical efficacy for the TSI platform. 
With the emergence of this information, together with data from further pre-clinical studies spanning a 
range of indications, many of these important ‘drugability’ questions will begin to be answered for this 
novel therapeutic platform.  
7. Conclusions 
BoNT/A is a major therapeutic product that can be widely used to treat various neurological and 
neuromuscular conditions. The therapeutic success of the BoNTs results from their specific and potent 
inhibition of neurotransmitter release from peripheral cholinergic neurons combined with a duration of 
action measured in months. The clinical utility of the neurotoxins is, however, severely constrained, 
both by their limited range of target cells and narrow therapeutic window. Advances over the last 
twenty years in understanding the structure and biology of CNTs, combined with developments in 
recombinant protein engineering is opening up opportunities to engineer novel therapeutic proteins 
based upon the unique pharmacological properties of the CNTs. One such opportunity, Targeted 
Secretion Inhibitors, is already progressing in the clinical setting and pre-clinically for a range of 
indications not treatable with neurotoxin products. These proteins will increase the medical benefits 
achieved through clinical application of the native neurotoxins, particularly BoNT/A, while removing 
the inherent toxicity and providing proteins with a much-improved therapeutic window. Harnessing the 
properties of the neurotoxins’ protein domains in novel recombinant proteins will lead to the creation 
of a completely new class of biologics. By inhibiting secretion, these will treat chronic conditions like 
chronic pain, which currently have few effective treatments. 
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